擬於A股科創板上市 沛嘉醫療-B(9996.HK)大漲近8%
格隆匯12月21日丨沛嘉醫療-B(9996.HK)盤中一度漲7.79%至26.3港元,股價創11月5日以來新高,市值166億港元。公司公告,於2020年12月18日,董事會已批准可能發行人民幣股份並將該等人民幣股份於科創板上市的初步建議。此外,公司還稱,公司於18日與法國醫療器械公司High Life訂立許可協議,High Life已就若干現正由許可方開發中的專有經導管二尖瓣置換術(TMVR)產品向本公司授出獨家許可。根據該協議,本公司有權(其中包括)在大中華區內製造、開發及商業化有關產品,而High Life則有權收取前期許可費及隨後里程碑付款作為回報。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.